Neuroninn Biosciences Co. Ltd. has synthesized G protein-coupled receptor GPR139 agonists reported to be useful for the treatment of anxiety disorders, depression, substance abuse and dependence and Parkinson’s disease.
Arcus Biosciences Inc. has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Les Laboratories Servier SAS and Vernalis (R&D) Ltd. have described induced myeloid leukemia cell differentiation protein Mcl-1 inhibitors acting as apoptosis inducers reported to be useful for the treatment of cancer and autoimmune diseases.
Aurigene Oncology Ltd. has divulged cyclin-dependent kinase 12 (CDK12) and/or cyclin-dependent kinase 13 (CDK13) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders, infections, amyotrophic lateral sclerosis, frontotemporal dementia, spinal and bulbar muscular atrophy, spinocerebellar ataxia and Huntington’s disease, among others.
A team of Johns Hopkins University researchers have filed for patent protection of a system and method to determine patient prioritization for triage during mass trauma events. The system and method may continuously monitor patient parameters to determine patient prioritization over time, which may improve the speed, quantity, and efficacy of life-saving interventions.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented phosphorylpurinone compounds acting as Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of cancer.
Incyte Corp. has developed fused tricyclic compounds acting as GTPase KRAS (mutant) inhibitors. As such, they are reported to be useful for the treatment of cancer, inflammation and immunological disorders.
RSS
